Basel, Switzerland–Lonza, a supplier to the pharmaceutical, biotech and specialty ingredients markets, announced that it has received a S&P BBB+ rating.
“This credit rating validates Lonza’s successful growth strategy, leadership positions in its Pharma & Biotech and Specialty Ingredients segments, and the Group’s attractive financial profile,”
said Rodolfo Savitzky, Lonza’s Chief Financial Officer, in a press release. “Lonza has been managing its capital structure with the overall aim of maintaining an investment grade credit profile, which S&P has now formally confirmed.”
Lonza says the S&P rating will increase transparency and comparability for global investors.
The full credit rating report is available on the S&P website.